Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infiltration of CD163‐, PD‐L1‐ and FoxP3‐positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Joana Rodrigues, Anna Nikkarinen, Peter Hollander, et al.
British Journal of Haematology (2021) Vol. 193, Iss. 3, pp. 520-531
Open Access | Times Cited: 17

Showing 17 citing articles:

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain, Michael Wang
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 638-656
Closed Access | Times Cited: 94
Macrophages and angiogenesis in human lymphomas
Doménico Ribatti, Roberto Tamma, Tiziana Annese, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Tumor-associated macrophages in lymphoma: From mechanisms to therapy
Xingfang Xiong, Xiaoli Xie, Zhiqiang Wang, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109235-109235
Closed Access | Times Cited: 18
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Khalil Saleh, Morgane Cheminant, David Chiron, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3229-3229
Open Access | Times Cited: 17
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Patrick Nylund, Anna Nikkarinen, Sara Ek, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
Anna Nikkarinen, Lavanya Lokhande, Rose‐Marie Amini, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5304-5313
Open Access | Times Cited: 7
The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
Salomé Decombis, Antonin Papin, Céline Bellanger, et al.
Haematologica (2022) Vol. 107, Iss. 12, pp. 2905-2917
Open Access | Times Cited: 11
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53</i>/p53 – a Nordic Lymphoma Group study
Joana Rodrigues, Peter Hollander, Lina Schmidt, et al.
Haematologica (2023)
Open Access | Times Cited: 5
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey
Andrea Duminuco, Alessandra Romano, Isacco Ferrarini, et al.
Annals of Hematology (2024)
Closed Access | Times Cited: 1
Quantification and profiling of early and late differentiation stage T-cells in mantle cell lymphoma reveals immunotherapeutic targets in subsets of patients
Lavanya Lokhande, Daniel Nilsson, Joana de Matos Rodrigues, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
Joana Rodrigues, Lavanya Lokhande, Lina Olsson, et al.
Blood Advances (2024) Vol. 8, Iss. 16, pp. 4370-4385
Open Access | Times Cited: 1
Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
Yannick Le Bris, Adeline Normand, Louise Bouard, et al.
eJHaem (2022) Vol. 3, Iss. 4, pp. 1165-1171
Open Access | Times Cited: 4
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
Anna Sandström Gerdtsson, Joana de Matos Rodrigues, Christian Winther Eskelund, et al.
Haematologica (2022) Vol. 108, Iss. 4, pp. 1092-1104
Open Access | Times Cited: 3
Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients
Lavanya Lokhande, Daniel Nilsson, Joana de Matos Rodrigues, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2289-2289
Open Access
Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma
Wei Zhang, Jinning Shi, Haining Wang, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 24, pp. 1323-1323
Open Access | Times Cited: 2
Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma
André Goy
Expert Review of Hematology (2021) Vol. 14, Iss. 10, pp. 927-943
Closed Access | Times Cited: 2
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies
David Qualls, Anita Kumar, Zachary D. Epstein‐Peterson
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 11, pp. 2515-2527
Open Access | Times Cited: 1
Page 1

Scroll to top